Islam Y Elgendy
Islam Y Elgendy is an expert in Cardiology at University of Kentucky (United States). As of October 2026, ScienceLeadR ranks Islam Y Elgendy in the top 1% of experts worldwide for Myocardial Ischemia, and in the top 1% of experts in the United States for Embolism and Thrombosis. Islam Y Elgendy has authored 613 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 2,198 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Internal Medicine - Biostatistics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 613
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Cardiovascular outcomes of SGLT2 inhibitors across the spectrum of myocardial infarction: A systematic review and meta-analysis. PMID 42928993 — diabetes mellitus, sodium-glucose transporter 2 inhibitors, mortality, hospitalization, stroke, myocardial infarction, heart failure, pharmaceutical preparations, heart, pharmacology | Br J Clin Pharmacol | 2026 | 0 |
| Comparative Outcomes of Self-Expanding Versus Balloon-Expandable Valves in Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. PMID 42928070 — constriction, pathologic, mortality, aortic valve stenosis, hospitalization, stroke, heart failure, heart, cardiovascular diseases, transcatheter aortic valve replacement | Cardiol Rev | 2026 | 0 |
| Timing of Nonculprit PCI for STEMI and Multivessel Disease. PMID 42863872 — st elevation myocardial infarction | JACC Cardiovasc Interv | 2026 | 0 |
| High-Potency P2Y12 Inhibitors Among Patients With Chronic Coronary Syndrome Undergoing PCI: An Analysis From the NCDR CathPCI Registry. PMID 42861503 — registries, myocardial infarction, ticagrelor, percutaneous coronary intervention, clopidogrel, prescriptions, arteries, odds ratio, coronary artery bypass | Circ Cardiovasc Interv | 2026 | 0 |
| After PCI in patients with ACS, short-duration DAPT followed by P2Y12 inhibitor monotherapy vs. standard DAPT reduces NACE. PMID 42832792 — internal medicine | Ann Intern Med | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 2
LeadR Networks
Main global connection map